Antiangiogenic therapy in diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 17, Issue 2, 2006, Pages 325-327

  Zent, Roy ^b   Pozzi, Ambra ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOSTATIN; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ALBUMINURIA; BLEEDING; DIABETIC NEPHROPATHY; DRUG INDICATION; EDITORIAL; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; THROMBOSIS;

EID: 33645452372     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005121290     Document Type: Editorial

References (30)

1. USRDS: The United States Renal Data System. Am J Kidney Dis 42: 1-230, 2003
2. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25: 971-1010, 2004
3. van Dijk C, Berl TL: Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord 5: 237-248, 2004
4. Osterby R, Asplund J, Bangstad HJ, Nyberg G, Rudberg S, Viberti GC, Walker JD: Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 14: 348-352, 1999
5. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, Watanabe T: Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45: 288-294, 2005
6. Satchell SC, Anderson KL, Mathieson PW: Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15: 566-574, 2004
7. Tsilibary EC: Microvascular basement membranes in diabetes mellitus. J Pathol 200: 537-546, 2003
8. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000, 2001
9. Berl T: Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: The case for AT1 receptor antagonist. J Am Soc Nephrol 15[Suppl 1]: S71-S76, 2004
10. Hilgers KF, Mann JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 13: 1100-1108, 2002
11. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y: Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 5: 307-323, 2005
12. Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Uemura M, Fukui H: Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats. Anticancer Res 25: 3335-3340, 2005
13. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin Cancer Res 7: 1073-1078, 2001
14. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H: Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 55: 5296-5301, 1995
15. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218, 1999
16. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516, 2004
17. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9: 49-58, 1998
18. Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, Vriese AS: A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2005 [Epub ahead of print]
19. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094, 2002
20. Gupta K, Zhang J: Angiogenesis: A curse or cure? Postgrad Med J 81: 236-242, 2005
21. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994
22. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997
23. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R: Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3: 589-601, 2003
24. Zhang SX, Wang JJ, Lu K, Mott R, Ma J-X: Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 17: 475-486, 2006
25. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y, Makino H: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53: 1831-1840, 2004
26. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H: Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54: 2891-2903, 2005
27. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 98: 1024-1029, 2001
28. Gonzalez-Gronow M, Grenett HE, Gawdi G, Pizzo SV: Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Exp Cell Res 303: 22-31, 2005
29. Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA: A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 272: 20395-20401, 1997
30. Maeshima Y, Colorado PC, Kalluri R: Two RGD-independent alphaV beta3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275:23745-23750, 2000